125 related articles for article (PubMed ID: 30454696)
1. Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity.
Chen J; Xu X; Chen J
Biochem Biophys Res Commun; 2018 Nov; 506(3):604-610. PubMed ID: 30454696
[TBL] [Abstract][Full Text] [Related]
2. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
Tan J; Ye J; Song M; Zhou M; Hu Y
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
[TBL] [Abstract][Full Text] [Related]
3. Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation.
Hu Z; Zhen L; Li Q; Han Q; Hua Q
Biochem Biophys Res Commun; 2019 Jun; 513(4):862-868. PubMed ID: 31000196
[TBL] [Abstract][Full Text] [Related]
4. Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.
Jin J; Xiang W; Wu S; Wang M; Xiao M; Deng A
Biochem Biophys Res Commun; 2019 Mar; 510(4):580-586. PubMed ID: 30739792
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of eIF4E signaling by ribavirin selectively targets lung cancer and angiogenesis.
Tan H; He L; Cheng Z
Biochem Biophys Res Commun; 2020 Aug; 529(3):519-525. PubMed ID: 32736668
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-β-Catenin Axis.
Shen X; Zhu Y; Xiao Z; Dai X; Liu D; Li L; Xiao B
Am J Med Sci; 2017 Aug; 354(2):182-189. PubMed ID: 28864377
[TBL] [Abstract][Full Text] [Related]
7. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
Xu M; Tao Z; Wang S; Jiang Y; Qu M
Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma.
Dai D; Chen H; Tang J; Tang Y
Biochem Biophys Res Commun; 2017 Jan; 482(4):1259-1264. PubMed ID: 27932243
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.
Cao J; Sun X; Zhang X; Chen D
Clin Transl Oncol; 2018 Jun; 20(6):761-767. PubMed ID: 29086249
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
[TBL] [Abstract][Full Text] [Related]
11. Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma.
Huq S; Casaos J; Serra R; Peters M; Xia Y; Ding AS; Ehresman J; Kedda JN; Morales M; Gorelick NL; Zhao T; Ishida W; Perdomo-Pantoja A; Cecia A; Ji C; Suk I; Sidransky D; Brait M; Brem H; Skuli N; Tyler B
Mol Cancer Ther; 2020 Sep; 19(9):1797-1808. PubMed ID: 32606016
[TBL] [Abstract][Full Text] [Related]
12. Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma.
Huq S; Kannapadi NV; Casaos J; Lott T; Felder R; Serra R; Gorelick NL; Ruiz-Cardozo MA; Ding AS; Cecia A; Medikonda R; Ehresman J; Brem H; Skuli N; Tyler BM
J Neurosurg Pediatr; 2021 Feb; 27(4):482-488. PubMed ID: 33545678
[TBL] [Abstract][Full Text] [Related]
13. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
14. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Volpin F; Casaos J; Sesen J; Mangraviti A; Choi J; Gorelick N; Frikeche J; Lott T; Felder R; Scotland SJ; Eisinger-Mathason TSK; Brem H; Tyler B; Skuli N
Oncogene; 2017 May; 36(21):3037-3047. PubMed ID: 27941882
[TBL] [Abstract][Full Text] [Related]
15. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Pettersson F; Yau C; Dobocan MC; Culjkovic-Kraljacic B; Retrouvey H; Puckett R; Flores LM; Krop IE; Rousseau C; Cocolakis E; Borden KL; Benz CC; Miller WH
Clin Cancer Res; 2011 May; 17(9):2874-84. PubMed ID: 21415224
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin targets eIF4E dependent Akt survival signaling.
Tan K; Culjkovic B; Amri A; Borden KL
Biochem Biophys Res Commun; 2008 Oct; 375(3):341-5. PubMed ID: 18706892
[TBL] [Abstract][Full Text] [Related]
17. Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy.
Wang G; Li Z; Li Z; Huang Y; Mao X; Xu C; Cui S
Biomed Pharmacother; 2017 Dec; 96():750-756. PubMed ID: 29049978
[TBL] [Abstract][Full Text] [Related]
18. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
[TBL] [Abstract][Full Text] [Related]
19. MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma.
Huang B; Jin P; Yi K; Duan J
Hum Exp Toxicol; 2023; 42():9603271231158047. PubMed ID: 36840478
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
